Literature DB >> 19168084

Can splenocytes enhance pancreatic beta-cell function and mass in 90% pancreatectomized rats fed a high fat diet?

Sunmin Park1, Sang Mee Hong, Il Sung Ahn.   

Abstract

AIMS: Recent studies have shown that splenocytes may act as a possible neogenic source with regard to beta-cells in rodent diabetic models. Accordingly, we sought to determine whether splenocytes played an important role in promoting beta-cell function and mass among type 2 diabetic rats with and without spleen. MAIN
METHODS: We randomly divided female 90% pancreatectomized (Px) Sprague Dawley rats into three groups: splenectomy (SPX), splenectomy plus the injection of male splenocytes (SPI), and no splenectomy (NSP). They were administered with 40 energy percent fat diets over the course of five weeks. At the end of the experimental period, insulin secretion capacity was measured by hyperglycemic clamp. At 6 h after BrdU(+) injection, the pancreas was prepared with 4% paraformaldehyde in order to perform immunohistochemistry. KEY
FINDINGS: SPX increased and sustained serum glucose levels more than NSP and SPI during oral glucose tolerance testing. During hyperglycemic clamp, first and second phase insulin secretion decreased in the SPX rats while splenocyte injections counteracted this. Beta-cell mass in the SPX group was reduced more than among NSP and SPI. This was the result of a decrease in the number of small beta-cell clusters in SPX, which is indicative of a decrease in beta-cell neogenesis. SIGNIFICANCE: Splenocytes play an important role with regard to the neogenesis of beta-cells in insulin deficient type 2 diabetic rats, although they are not critical for beta-cell regeneration.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19168084     DOI: 10.1016/j.lfs.2008.12.022

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  5 in total

Review 1.  Stem cells in the spleen: therapeutic potential for Sjogren's syndrome, type I diabetes, and other disorders.

Authors:  Denise L Faustman; Miriam Davis
Journal:  Int J Biochem Cell Biol       Date:  2010-06-18       Impact factor: 5.085

2.  Proteomics identifies multipotent and low oncogenic risk stem cells of the spleen.

Authors:  Francisco Dieguez-Acuña; Shohta Kodama; Yoshiaki Okubo; Ana Cristina Paz; Steven P Gygi; Denise L Faustman
Journal:  Int J Biochem Cell Biol       Date:  2009-12-18       Impact factor: 5.085

3.  Spleen extracellular matrix provides a supportive microenvironment for β-cell function.

Authors:  Layasadat Khorsandi; Mahmoud Orazizadeh; Darioush Bijan Nejad; Abbas Heidari Moghadam; Fereshteh Nejaddehbashi; Yousef Asadi Fard
Journal:  Iran J Basic Med Sci       Date:  2022-09       Impact factor: 2.532

Review 4.  Middle-preserving pancreatectomy: report of two cases and review of the literature.

Authors:  Kun Cheng; Bai-yong Shen; Cheng-hong Peng; Li-ma Na; Dong-feng Cheng
Journal:  World J Surg Oncol       Date:  2013-05-23       Impact factor: 2.754

5.  Risk factors for new-onset diabetes mellitus after distal pancreatectomy.

Authors:  Menghua Dai; Cheng Xing; Ning Shi; Shunda Wang; Guangdong Wu; Quan Liao; Taiping Zhang; Ge Chen; Wenming Wu; Junchao Guo; Ziwen Liu
Journal:  BMJ Open Diabetes Res Care       Date:  2020-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.